Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects
Ormutivimab is the first recombinant human anti-rabies monoclonal antibody (rhRIG) approved for clinical application in China. In this study, a population pharmacodynamic (PPD) model was established to compare the neutralizing antibody activities of Ormutivimab and human rabies immunoglobulin (HRIG)...
Main Authors: | Junnan Zhang, Nianmin Shi, Guohua Li, Li Li, Yunhua Bai, Liqing Yang, Weimin Zhao, Jian Gao, Jingshuang Wei, Wei Zhao, Lili Zhai, Peiyuan Huo, Lemin Ren, Lan Yu, Yufeng Li |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/8/1218 |
Similar Items
-
Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial
by: Xiaoqiang Liu, et al.
Published: (2023-09-01) -
Pharmacokinetic study and preliminary evaluation of safety and efficacy of the recombinant human monoclonal antibodies against rabies virus (rhRIG) in Chinese healthy population: A randomized, single-blinded, placebo-controlled phase Ia clinical trial
by: Xi Chen, et al.
Published: (2023-09-01) -
Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposureResearch in context
by: Gagandeep Kang, et al.
Published: (2023-07-01) -
In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models
by: Tzu-Yuan Chao, et al.
Published: (2020-02-01) -
Defining the volume of rabies immunoglobulins/ rabies monoclonal antibodies requirement for wound infiltration of category III animal exposures – an exploratory study
by: Ravish S. Haradanhalli, et al.
Published: (2021-12-01)